Larotrectinib OK'd for Cancers with TRK Fusions.
Larotrectinib, a first-in-class TRK inhibitor, received accelerated approval for patients of all ages with solid tumors harboring NTRK fusions. It's the first tissue-agnostic marketing authorization for a targeted therapy and the first time a drug's initial approval has been site-independent.